MetaCap

Regentis Biomaterials Ltd. (RGNT)

NYSE: RGNTHealth CareIndustrial SpecialtiesUSD

0.7186-0.1211 (-14.42%)

At close: Nov 20, 3:59 PM ET · Delayed 15 min

RGNT stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.46
52-week range
0.712 – 15.50
Day range
0.7123 – 0.8889
Volume / Avg
122.34K / 49.60K
Beta
—

52-week range

$0.712$15.50

RGNT stock today

Shares of Regentis Biomaterials (RGNT) finished lower on Nov 20 at $0.7186, a drop of 14.42% or $0.1211 per share, versus the S&P 500's 3.70% decline. Volume was 2.5x the average at 122.34K shares, a sign of unusually heavy trading. Shares are 95.4% below their 52-week high of $15.50, set on Jun 15, 2026 and 0.9% above the 52-week low of $0.712, near the bottom of the past year's range.

RGNT is down 89.3% year to date, underperforming the S&P 500 (+1.2%). Regentis Biomaterials has posted a net loss over the last twelve months (EPS of -$2.46), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Regentis Biomaterials

Company profile

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.

Industry
Industrial Specialties
CEO
Dr. Ehud Geller Ph.D.
Headquarters
Herzliya
IPO year
2025

Financial highlights

Full financials

Regentis Biomaterials reported a net loss of $13.6 million, compared with net income of $4.8 million a year earlier. Diluted earnings per share came in at -$24.16, down from $1.72.

Regentis Biomaterials annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue———
Growth———
Net income$-13.65M$4.80M$-4.13M
EPS (diluted)$-24.16$1.72$-24.09

Analyst forecast

Forecast

Consensus

none

Avg. price target

$10.00+1291.59%

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Regentis Biomaterials peers

Health Care sector
RGNT peer companies
CompanyPrice% ChgMarket capCompare
LFWDLifeward Ltd.2.80-5.30%$7.96Mvs RGNT
BBLGBone Biologics Corp0.2685-2.40%$909.96Kvs RGNT
FGIFGI Industries Ltd.4.90-6.84%$9.46Mvs RGNT
OPHICollPlant Biotechnologies Ltd3.13-2.49%$9.63Mvs RGNT
HSCSHeartSciences Inc.1.81-10.84%$10.42Mvs RGNT
CUPRCuprina Holdings (Cayman) Limited Class A1.41-6.00%$10.79Mvs RGNT
TLIHTen-League International Holdings Limited5.79+0.70%$17.03Mvs RGNT
MLSSMilestone Scientific Inc.0.24-0.83%$21.75Mvs RGNT

Indexes, lists and sector

Regentis Biomaterials stock FAQ

What is Regentis Biomaterials's stock price today?

RGNT last traded at $0.7186 as of Nov 20, 3:59 PM EST, down 14.42% on the day. Prices are delayed at least 15 minutes.

Who is Regentis Biomaterials's CEO?

Dr. Ehud Geller Ph.D. is the chief executive officer of Regentis Biomaterials Ltd..

What is the RGNT 52-week high?

The 52-week high for RGNT is $15.50 and the 52-week low is $0.712. The stock is currently 95.4% below its high.

Compare RGNT